Drug Trial Radar · NCT03722576
Vidofludimus Calcium for Primary Sclerosing Cholangitis
Last checked: Nov 19, 2026Latest source record: Oct 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jun 17, 2019
Primary completion
Jun 30, 2020
Study completion Jun 30, 2020
Sponsor
- Lead sponsor
- Elizabeth CareyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Arizona State University
- First posted
- Oct 29, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.
Conditions
- Primary Sclerosing Cholangitis
Interventions
Vidofludimus calciumDrug
During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subjects Who Experience a Positive Outcome as Measured by Combination of Serum Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST) Levels.Time frame: Baseline to 24 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Phoenix, Arizona
Arizona State University
Tempe, Arizona
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.